DDInter706 DDInter704
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Exenatide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Digoxin
Digoxin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Exenatide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is upregulated by {v} (Compound) Everolimus
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dobutamine
Dobutamine {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Thrombocytopenia {u} (Side Effect) is caused by {v} (Compound) Everolimus
Exenatide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lovastatin
Lovastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) FKBP1A
FKBP1A {u} (Gene) is bound by {v} (Compound) Everolimus
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) upregulates {v} (Gene) BTG1
BTG1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Etonogestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Exenatide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Exenatide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Everolimus (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Everolimus (Compound)
Exenatide may cause a minor interaction that can limit clinical effects when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds FKBP1A (Gene) and FKBP1A (Gene) is bound by Everolimus (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) upregulates BTG1 (Gene) and BTG1 (Gene) is upregulated by Everolimus (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)